Namodenoson

Namodenoson
Clinical data
Other names	Chloro-IB-MECA; 2-Cl-IB-MECA
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (2S,3S,4R,5R)-5-[2-Chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide;
CAS Number	163042-96-4;
PubChem CID	3035850;
IUPHAR/BPS	457;
DrugBank	DB12885;
ChemSpider	2299989;
UNII	Z07JR07J6C;
KEGG	D11128;
ChEMBL	ChEMBL431733;
CompTox Dashboard (EPA)	DTXSID80167504 ;
ECHA InfoCard	100.162.091
Chemical and physical data
Formula	C18H18ClIN6O4
Molar mass	544.73 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O;
	InChI InChI=1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1; Key:IPSYPUKKXMNCNQ-PFHKOEEOSA-N;

Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is developed by Can-Fite for non-alcoholic fatty liver disease,^[1] liver cancer,^[2] and pancreatic cancer.^[3]